Dexcom (DXCM) Cash & Current Investments (2010 - 2026)

Dexcom (DXCM) has reported Cash & Current Investments for 17 consecutive years, with $1.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Current Investments fell 33.53% year-over-year to $1.9 billion in Q2 2026; TTM through Jun 2026 was $1.9 billion, a 33.53% decrease from a year earlier, with the FY2025 full-year figure at $2.0 billion, down 22.51% from the prior year.
• Cash & Current Investments was $1.9 billion for Q2 2026 at Dexcom, down from $2.4 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $3.6 billion in Q2 2023 and troughed at $1.9 billion in Q2 2026.
• A 5-year average of $2.7 billion and a median of $2.7 billion in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments soared 36.61% in 2023 and sank 33.53% in 2026, its largest moves.
• Over 5 years, Cash & Current Investments stood at $2.5 billion in 2022, then gained by 10.91% to $2.7 billion in 2023, then dropped by 5.31% to $2.6 billion in 2024, then dropped by 22.51% to $2.0 billion in 2025, then retreated by 2.59% to $1.9 billion in 2026.
• The last three Cash & Current Investments figures came in at $1.9 billion (Q2 2026), $2.4 billion (Q1 2026), and $2.0 billion (Q4 2025), per Business Quant data.